Mount Sinai’s menopause page describes clinical care for concerns including hot flashes and sexual dysfunction. It also discusses research into why hot-flash experiences differ between women. These are related subjects, but an explanation of symptoms is not the same evidence as a tested treatment or a product offered to a patient.
This review was completed September 29, 2026. It examines the service through that distinction and states plainly that its public record does not identify a particular nonhormonal medicine. No clinical trial participation, prescription, pharmacy supply or outcome was verified for an individual.
The actual clinical offer concerns assessment and symptom management
Mount Sinai’s menopause service page describes a team approach to developing an individual plan. It identifies hot flashes, abnormal bleeding and sexual dysfunction among the concerns patients may experience. That establishes relevant clinical care independently of the page’s research section.
The visit-goals guide helps distinguish the concern prompting an appointment from the intervention that might follow. These symptoms should not be treated as one diagnosis or a request for one medicine. In particular, the presence of bleeding on a service menu does not make it an ordinary hot-flash treatment question or a reason to select a nonhormonal drug without professional assessment.
A research question about symptoms does not demonstrate a treatment effect
The research description discusses variation in hot flashes and possible genetic contributions using information associated with the SWAN study. It does not present a trial of a named nonhormonal medicine supplied by the clinic. The study’s subject and a future prescription should remain separate.
The page also contains a study-duration statement that should not be used as a current research-calendar claim. This review does not infer active recruitment, eligibility or access to an investigational product. Hopkins’ review examines another service whose broad clinical scope leaves the exact medicine unanswered. Research activity and institutional reputation do not fill that gap or prove superior symptom outcomes.
The nonhormonal category needs a defined intervention
The Mount Sinai service record does not name an exact nonhormonal prescription or a standard drug family for its patients. That limitation remains visible in this directory entry. A reader’s preference to explore options without hormones does not supply the missing product identity.
Our medicine-family guide distinguishes treatment categories without claiming that Mount Sinai offers every one. The FDA’s current overview describes several approved nonhormonal therapies, but national approval is not a clinic formulary, a pharmacy-stock record or confirmation of personal suitability. The actual intervention would need to be identified before its evidence and practical arrangements could be assessed.
The outcome in a source needs to match the goal being discussed
The 2023 Menopause Society abstract evaluates nonhormonal options for vasomotor symptoms. A finding within that scope is not automatically evidence for treating sexual pain, an unexplained bleeding concern or every cause of disrupted sleep. Those goals may require different assessments and evidence.
This also prevents a service’s broad range of concerns from becoming an implied list of indications for one medicine. Northwestern’s review considers explicit therapy roles within a varied program. A useful comparison asks what each intervention is intended to change. It does not rank providers by how many symptoms their websites mention or assume that one successful outcome establishes another.
Newer products require current records rather than an older menu
A dated professional statement can still inform an evidence discussion, but it cannot include developments that occurred later. The FDA overview recognizes multiple approved nonhormonal medicines. This review does not repeat the outdated claim that one older product is the only approved option.
The elinzanetant evidence guide addresses a newer named medicine separately from Mount Sinai’s clinical offering. Its availability in a regulatory record does not establish that this clinic prescribes it or that an earlier symptom study evaluated it. Product approval, study findings and local access are different records that need an explicit connection before a service claim can be made.
Safety follow-up belongs to the particular proposal
The FDA fezolinetant safety record describes serious liver-injury risk and testing responsibilities for that specific medicine. It demonstrates why nonhormonal should not be understood as a risk-free category. It does not establish that Mount Sinai uses that product or explain this clinic’s monitoring arrangements.
Our monitoring-context guide keeps the professional responsibilities visible without giving an individual schedule. Once a treatment is proposed, its own warnings and interaction questions would matter alongside the symptom goal. This review does not use the absence of a public protocol to assert unsafe care; it identifies information that cannot be verified from the broad service page.
A regional service needs a concrete appointment and cost explanation
Mount Sinai’s menopause location information identifies New York City practices. That is a regional clinical footprint, not evidence of unrestricted national prescribing. The relevant office would need to confirm the appropriate appointment and access conditions.
The reviewed service information does not establish a combined price for consultation, additional assessment, medication or any necessary follow-up. No insurance claim, selected pharmacy charge or booking was tested. The supported conclusion is a real menopause service with an unresolved nonhormonal product choice. Its research description can remain informative without being turned into a medicine recommendation, an outcome promise or proof of access to a particular treatment.
Follow the evidence
Source documents
Read each source for the product, population and purpose it describes. Commercial pages document advertised terms, not individual care outcomes.
- Mount Sinai — MenopauseOfficial clinical service description, accessed September 29, 2026; an individual prescription, access arrangement, full price and outcome are not established. Published treatment categories are not an all-product formulary. · Checked 2026-09-29
- FDA — Hormone Replacement Therapies Can Help Women with Bothersome Menopausal SymptomsCurrent federal consumer overview, accessed September 29, 2026; confirms multiple approved nonhormonal therapies. Not a clinic’s formulary, a treatment protocol or proof all requested hormone-label changes are completed. · Checked 2026-09-29
- The 2023 nonhormone therapy position statement of The North American Menopause Society — PubMed abstractPrimary professional position-statement abstract, published 2023; vasomotor-symptom scope only. Full article not retrieved. Predates later drug approvals; does not evaluate these clinics or equate all forms of counseling. · Checked 2026-09-29
- FDA — Fezolinetant serious liver-injury safety communicationFederal primary safety communication; the retrieved text displays the September 12, 2024 communication. Used for serious liver-risk and testing context only; current boxed warning and contraindications are separately supported by the current exact DailyMed label where discussed. · Checked 2026-09-29
- Mount Sinai — Menopause LocationsOfficial clinical location or appointment information, accessed September 29, 2026; regional access and preparation are distinct from medicine eligibility or monitoring. · Checked 2026-09-29